Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2022-07-19 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于对2020年可转债募集资金投资项目之“老店升级改造项目”变更的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change in the use of funds raised from a 2020 convertible bond issuance by 益丰大药房连锁股份有限公司. It details the original investment project (老店升级改造项目) and the new project (上海益丰医药产品智能分拣中心项目), including investment amounts, reasons for the change, approvals by the board, supervisory board, independent directors, and the sponsor. The document is a formal public announcement about the change in the use of raised capital and the related approvals, not a full financial report or detailed financial statements. It does not contain comprehensive financial data or results but focuses on the capital investment project update and related governance approvals. Therefore, it fits best under Capital/Financing Update (CAP). The document length (6796 characters) and content confirm it is a detailed announcement rather than a brief notice or a full annual/interim report.
2022-07-19 Chinese
中信证券股份有限公司关于益丰大药房连锁股份有限公司变更部分募集资金投资项目的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding a change in the use of part of the funds raised by Yifeng Pharmacy Chain Co., Ltd. through a convertible bond issuance. It references regulatory approvals, specific investment projects, amounts, and changes in the allocation of raised funds. The document includes detailed financial figures, project descriptions, risk assessments, and approvals by the board and independent directors. It is not a full annual or interim report, nor is it a simple announcement or certification. It is a formal audit or verification report related to the use of raised funds, consistent with an Audit Report / Information filing. The length (5462 characters) and content support this classification rather than a brief announcement or regulatory filing. H1 2022
2022-07-19 Chinese
独立董事关于第四届董事会第十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting matters, including changes to bond fundraising investment projects and the removal of a senior management officer. It references compliance with company bylaws, securities regulations, and approval procedures. The content focuses on board and management decisions rather than financial results or reports. The document length is short (909 characters) and it is not a report itself but an opinion related to board matters. Therefore, it fits best under Board/Management Information (MANG).
2022-07-19 Chinese
益丰药房第四届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 益丰大药房连锁股份有限公司 regarding decisions made in their 12th meeting of the 4th Supervisory Board. It details voting results on changes to the use of funds raised from convertible bonds and an acquisition of a 70% stake in another company. The document includes meeting attendance, voting results, and compliance statements. It is not a full financial report, audit report, or earnings release. It is also not a notice of dividend, capital change, or management change. The content fits best with a regulatory announcement of board/committee meeting resolutions, which aligns with the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories. The document length is short (1884 characters), and it is a formal announcement of meeting resolutions rather than a detailed report or presentation.
2022-07-19 Chinese
益丰药房关于免去高级管理人员职务的公告
Board/Management Information Classification · 100% confidence The document is an announcement from the company's board regarding the removal of a senior management officer (vice president). It specifically states the decision made at a board meeting to relieve the individual of their duties and confirms no impact on operations. There is no financial data, no mention of reports or filings, and the content is focused on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and the content is clearly about management changes, not a report or announcement of a report.
2022-07-19 Chinese
益丰药房关于收购唐山市德顺堂医药连锁有限公司重组后新公司70%股权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 70% equity in a newly restructured company by the listed company 益丰大药房连锁股份有限公司. It includes transaction details, parties involved, financial data, valuation, payment arrangements, and strategic impact. The content focuses on a capital transaction involving acquisition and restructuring, with no indication of it being a full annual or interim report, earnings release, or other report types. It is not a simple announcement of a report publication but a substantive disclosure of a financing and capital transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-07-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.